+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Migraine Drugs Market - Global Forecast 2026-2032- Product Image
Migraine Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Migraine Drugs Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968814
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Migraine Drugs Market is projected to reach USD 5.98 Billion in 2026. It is expected to continue growing at a CAGR of 8.93%, reaching USD 10.01 Billion by 2032.

Migraine drugs occupy one of the most clinically active areas of neurology because migraine is common, disabling, recurrent, and often undertreated. The Global Burden of Disease study has consistently ranked migraine among the leading causes of years lived with disability worldwide, and migraine is especially burdensome among working-age adults and women. This creates durable need for acute migraine treatments, preventive migraine therapies, and better patient identification across primary care, neurology, retail pharmacy, and digital health channels.

The landscape has moved beyond historical reliance on nonsteroidal anti-inflammatory drugs, triptans, ergots, antiemetics, and off-label preventive medicines. Calcitonin gene-related peptide (CGRP) monoclonal antibodies, oral gepants, nasal gepants, ditans, and onabotulinumtoxinA for chronic migraine have expanded the migraine drug landscape with more mechanism-based options. For life sciences leaders, payer organizations, and care delivery networks, the strategic priority is no longer only product availability; it is matching the right migraine medicine to the right patient at the right point in the treatment journey.

Transformative Shifts in the Migraine Treatment Landscape

The most important shift in the migraine drugs landscape is the transition from broad symptom control to mechanism-led migraine therapy. CGRP-targeted medicines have validated migraine-specific biology in both acute and preventive care, while gepants have added non-vasoconstrictive options that may be clinically relevant for patients who cannot use or do not respond to triptans. This has changed prescribing pathways, competitive positioning, and patient expectations.

A second shift is the movement toward patient-centered treatment endpoints. Reduction in monthly migraine days remains a key clinical measure, but stakeholders increasingly evaluate onset of relief, freedom from the most bothersome symptom, tolerability, medication-overuse risk, adherence, and functional recovery. As more therapies compete within acute and preventive segments, real-world evidence, formulary access, prior authorization design, and persistence data are becoming as influential as pivotal trial efficacy.

Cumulative Impact of Artificial Intelligence on Migraine Drugs

Artificial intelligence is becoming a cumulative enabler across migraine drug discovery, clinical development, diagnosis support, and treatment optimization. In research, AI-enabled analytics can help identify molecular targets, analyze genomics and proteomics data, and improve trial protocol design by refining eligibility criteria, comparator selection, and endpoint sensitivity. In development programs, machine learning can support site selection, patient recruitment, safety signal detection, and real-world evidence generation from claims, electronic health records, and patient-reported outcomes.

In care delivery, AI has practical value when it improves migraine characterization without replacing clinical judgment. Digital headache diaries, wearable data, and natural-language processing of clinical notes can help detect attack patterns, triggers, medication use, and response to therapy. The near-term opportunity is decision support that helps clinicians distinguish episodic migraine, chronic migraine, medication-overuse headache, and comorbid conditions while aligning treatment with evidence-based guidelines, patient preferences, and payer requirements.

Key Regional Insights Across Migraine Drug Adoption

North America remains a highly influential region for migraine drugs because the United States has been an early launch environment for CGRP monoclonal antibodies, gepants, and newer acute therapies, supported by a large specialist base, extensive clinical research activity, and mature pharmacy benefit infrastructure. Canada follows evidence-based reimbursement pathways that can moderate uptake but strengthen value scrutiny. Across the region, access management, copay design, prior authorization, and step-therapy rules shape real-world utilization of acute migraine treatment and preventive migraine therapy.

Europe combines strong neurology expertise with centralized and country-specific health technology assessment, making comparative value, clinical benefit, and cost-effectiveness central to adoption. The European Union emphasizes regulatory consistency, evidence generation, pharmacovigilance, and post-authorization monitoring, while the United Kingdom, Germany, France, Italy, and Spain apply distinct reimbursement and prescribing controls. Asia-Pacific is expanding as Japan, China, South Korea, Australia, India, and ASEAN countries improve diagnosis, physician education, and access to migraine therapeutics, although affordability and specialist availability vary widely across urban and rural settings. Latin America, the Middle East, and Africa show meaningful unmet need, with adoption linked to private healthcare expansion, public reimbursement evolution, hospital formulary inclusion, physician education, and broader availability of branded and generic migraine medicines.

Key Group Insights for Strategic Migraine Market Planning

Within ASEAN, migraine drug demand is shaped by urbanization, expanding private healthcare capacity, increasing use of digital health tools, and wider recognition of neurological disorders, but access to specialist-led preventive care remains uneven across member countries. The GCC benefits from high healthcare investment, strong hospital infrastructure, and rising adoption of innovative medicines, while reimbursement policy, national procurement priorities, and specialty prescribing pathways influence speed of patient access.

The European Union is a pivotal group for migraine drugs because harmonized regulatory standards coexist with country-level reimbursement decisions and health technology assessment processes. BRICS markets combine large patient populations with different levels of affordability, local manufacturing capacity, clinical guideline adoption, and formulary inclusion, creating both scale and access challenges. G7 countries concentrate much of the clinical research, branded therapy uptake, payer evidence generation, and guideline influence for migraine therapeutics. NATO members overlap substantially with advanced North American and European markets, where supply chain resilience, regulatory alignment, pharmacovigilance systems, and health system capacity support more consistent availability of migraine drugs.

Key Country Insights in the Migraine Drugs Market

The United States leads global commercialization of innovative migraine drugs, with broad availability of CGRP inhibitors, gepants, ditans, onabotulinumtoxinA for chronic migraine, and specialty pharmacy pathways, but payer controls strongly affect prescribing and persistence. Canada emphasizes clinical value and reimbursement review, while Mexico and Brazil represent important Latin American markets where specialist access, private insurance coverage, public procurement, and availability of established triptans and generics determine uptake. In Europe, the United Kingdom, Germany, France, Italy, and Spain each maintain strong neurology systems, but national health technology assessment, regional prescribing rules, and reimbursement criteria shape patient access; Russia has a sizeable migraine population but faces market-specific regulatory, supply, and access constraints.

In Asia-Pacific, China and India offer scale but require affordability strategies, physician education, primary care diagnosis, and wider availability of evidence-based acute and preventive migraine treatments. Japan has high clinical sophistication and an aging population that elevates the need for well-tolerated therapies with clear safety profiles. Australia supports evidence-based access through national reimbursement systems, while South Korea combines advanced healthcare infrastructure with increasing adoption of innovative neurology medicines. Across all countries, the central challenge is converting migraine prevalence into diagnosed, appropriately treated, adherent, and outcomes-monitored patient populations.

Actionable Recommendations for Migraine Drug Industry Leaders

Industry leaders should prioritize differentiated clinical positioning rather than compete only on class participation. Acute migraine therapies need evidence on speed of onset, sustained pain freedom, relief from the most bothersome symptom, functional recovery, tolerability, and suitability for patients with cardiovascular risk factors. Preventive therapies should demonstrate durable reductions in monthly migraine days, improved quality of life, low discontinuation, and practical administration options that fit patient preferences.

Commercial teams should integrate market access evidence early, including real-world adherence, emergency department avoidance, workplace productivity, reduction in medication overuse, and patient-reported outcomes. Medical affairs organizations can create value by supporting clinician education on migraine diagnosis, chronic migraine identification, medication-overuse headache, comorbid depression and anxiety, and rational sequencing of triptans, gepants, ditans, CGRP monoclonal antibodies, and botulinum toxin. Partnerships with digital headache platforms, specialty pharmacies, and patient support programs can strengthen adherence while improving outcomes documentation.

Research Methodology for Migraine Drugs Market Insights

This executive summary is built from a triangulated research approach using publicly available regulatory information, clinical guideline trends, peer-reviewed migraine burden evidence, product class analysis, and market access observations. Core disease-burden context is aligned with sources such as the Global Burden of Disease study and the World Health Organization’s public health framing of headache disorders, while therapy landscape insights reflect approved drug classes, evidence-based treatment pathways, and established clinical use patterns. The methodology emphasizes data validation through cross-checking of epidemiology, regulatory approvals, therapeutic mechanisms, guideline recommendations, reimbursement dynamics, and regional healthcare infrastructure.

Conclusion: The Future of Migraine Drug Innovation

The migraine drugs market is entering a more sophisticated phase defined by targeted mechanisms, patient segmentation, payer evidence requirements, and digital support. High disease burden, persistent underdiagnosis, variable treatment access, and the need for better acute and preventive outcomes sustain demand across developed and emerging healthcare systems.

Future leadership will depend on evidence quality, access strategy, treatment personalization, and the ability to demonstrate measurable value beyond symptom reduction. Organizations that combine innovative migraine therapeutics with real-world data, physician education, equitable access planning, and patient support will be best positioned to improve outcomes and strengthen long-term relevance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Migraine Drugs Market, by Drug Class
7.1. Introduction
7.2. CGRP Monoclonal Antibodies
7.2.1. Eptinezumab
7.2.2. Erenumab
7.2.3. Fremanezumab
7.2.4. Galcanezumab
7.3. Ditans
7.4. Ergot Derivatives
7.4.1. Dihydroergotamine
7.4.2. Ergotamine
7.5. Gepants
7.5.1. Atogepant
7.5.2. Rimegepant
7.5.3. Ubrogepant
7.6. NSAID
7.6.1. Diclofenac
7.6.2. Ibuprofen
7.6.3. Naproxen
7.7. Triptans
7.7.1. Almotriptan
7.7.2. Eletriptan
7.7.3. Frovatriptan
7.7.4. Naratriptan
7.7.5. Rizatriptan
7.7.6. Sumatriptan
7.7.7. Zolmitriptan
8. Migraine Drugs Market, by Types
8.1. Introduction
8.2. Injectable
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Nasal
8.4. Oral
8.4.1. Capsule
8.4.2. Tablet
8.5. Topical
9. Migraine Drugs Market, by Indication
9.1. Introduction
9.2. Acute Treatment
9.3. Preventive Treatment
10. Migraine Drugs Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Pediatric
11. Migraine Drugs Market, by End User
11.1. Introduction
11.2. Hospitals & Clinics
11.3. Home Care Settings
11.4. Specialty Centers
12. Migraine Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Offline
12.3. Online
13. Migraine Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Migraine Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Migraine Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Almirall S.A.
17.3. Amgen Inc.
17.4. Apotex Inc.
17.5. AstraZeneca plc
17.6. Aurobindo Pharma Limited
17.7. Bayer AG
17.8. Bristol-Myers Squibb Company
17.9. Cipla Limited
17.10. Dr. Reddy's Laboratories Ltd.
17.11. Eli Lilly and Company
17.12. Esteve Pharmaceuticals S.A.
17.13. Ferrer Internacional S.A.
17.14. GlaxoSmithKline plc
17.15. Grünenthal GmbH
17.16. Hikma Pharmaceuticals PLC
17.17. Ipsen S.A.
17.18. Johnson & Johnson
17.19. Lundbeck A/S
17.20. Lupin Limited
17.21. Merck & Co., Inc.
17.22. Novartis AG
17.23. Pfizer Inc.
17.24. Sanofi S.A.
17.25. Sun Pharmaceutical Industries Ltd.
17.26. Teva Pharmaceutical Industries Ltd.
17.27. Torrent Pharmaceuticals Ltd.
17.28. Viatris Inc.
17.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2032 (%)
FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CGRP MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL EPTINEZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL EPTINEZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL EPTINEZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ERENUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ERENUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ERENUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL FREMANEZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL FREMANEZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL FREMANEZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GALCANEZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GALCANEZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GALCANEZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DITANS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DITANS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DITANS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ERGOT DERIVATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DIHYDROERGOTAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ERGOTAMINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ERGOTAMINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ERGOTAMINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GEPANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GEPANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GEPANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL ATOGEPANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL ATOGEPANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL ATOGEPANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL RIMEGEPANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL RIMEGEPANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL RIMEGEPANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL UBROGEPANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL UBROGEPANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL UBROGEPANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NSAID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL NSAID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL NSAID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DICLOFENAC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DICLOFENAC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DICLOFENAC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL IBUPROFEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL IBUPROFEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL IBUPROFEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NAPROXEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL NAPROXEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL NAPROXEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL TRIPTANS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL TRIPTANS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TRIPTANS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ALMOTRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ALMOTRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ALMOTRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ELETRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ELETRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ELETRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL FROVATRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL FROVATRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL FROVATRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NARATRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL NARATRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NARATRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RIZATRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RIZATRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RIZATRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SUMATRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL SUMATRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SUMATRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ZOLMITRIPTAN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL NASAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL NASAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL TABLET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL TABLET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ACUTE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ACUTE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL ACUTE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL PREVENTIVE TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 150. EUROPE MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 153. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 154. EUROPE MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 155. EUROPE MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 156. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 158. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 159. EUROPE MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 160. EUROPE MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 161. EUROPE MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 162. EUROPE MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 163. EUROPE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 166. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 167. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 168. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 169. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 170. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 171. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 180. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 181. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 182. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 183. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 184. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 185. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 186. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 187. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 188. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 189. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. AFRICA MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 193. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 194. AFRICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 195. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 196. AFRICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 197. AFRICA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 198. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 199. AFRICA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 200. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 201. AFRICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 202. AFRICA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 203. AFRICA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 204. AFRICA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 206. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 209. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 210. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 211. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 212. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 213. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 214. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 215. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 216. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 217. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 218. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 219. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 221. NATO MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. NATO MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 223. NATO MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 224. NATO MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 225. NATO MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 226. NATO MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 227. NATO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 228. NATO MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 229. NATO MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 230. NATO MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 231. NATO MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 232. NATO MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 233. NATO MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. NATO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. G7 MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 236. G7 MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 237. G7 MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 238. G7 MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 239. G7 MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 240. G7 MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 241. G7 MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 242. G7 MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 243. G7 MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 244. G7 MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 245. G7 MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 246. G7 MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 247. G7 MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. G7 MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. BRICS MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. BRICS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 251. BRICS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 252. BRICS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 253. BRICS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 254. BRICS MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 255. BRICS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 256. BRICS MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 257. BRICS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 258. BRICS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 259. BRICS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 260. BRICS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 261. BRICS MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. BRICS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 270. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 271. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 272. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 273. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 274. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. ASEAN MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 279. ASEAN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 280. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 281. ASEAN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 282. ASEAN MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 283. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 284. ASEAN MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 285. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 286. ASEAN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 287. ASEAN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 288. ASEAN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 289. ASEAN MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. ASEAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 291. GCC MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 292. GCC MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. GCC MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 294. GCC MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 295. GCC MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 296. GCC MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 297. GCC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 298. GCC MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 299. GCC MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 300. GCC MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 301. GCC MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 302. GCC MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 303. GCC MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 304. GCC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 305. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 306. CHINA MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 307. CHINA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 308. CHINA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 309. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 310. CHINA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 311. CHINA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 312. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 313. CHINA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 314. CHINA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 315. CHINA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 316. CHINA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 317. CHINA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 318. CHINA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 319. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 320. UNITED STATES MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 322. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 323. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 324. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 325. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 326. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 327. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 328. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 329. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 330. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 331. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. JAPAN MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 336. JAPAN MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 337. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 338. JAPAN MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 339. JAPAN MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 340. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 341. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 342. JAPAN MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 343. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 344. JAPAN MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 345. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 346. JAPAN MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 347. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 348. INDIA MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. INDIA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 350. INDIA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 351. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 352. INDIA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 353. INDIA MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 354. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 355. INDIA MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 356. INDIA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 357. INDIA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 358. INDIA MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 359. INDIA MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 360. INDIA MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 361. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 362. GERMANY MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 364. GERMANY MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 365. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 366. GERMANY MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 367. GERMANY MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 368. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 369. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 370. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 371. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 372. GERMANY MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 373. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 374. GERMANY MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 375. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 376. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 377. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 378. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 379. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2017-2032 (USD MILLION)
TABLE 380. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2017-2032 (USD MILLION)
TABLE 381. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY NSAID, 2017-2032 (USD MILLION)
TABLE 382. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2017-2032 (USD MILLION)
TABLE 383. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY TYPES, 2017-2032 (USD MILLION)
TABLE 384. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 385. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 386. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 387. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 388. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 389. UNITED KINGDOM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 390. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 391. AUSTRALIA MIGRAINE DRUGS

Companies Mentioned

  • AbbVie Inc.
  • Almirall S.A.
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Esteve Pharmaceuticals S.A.
  • Ferrer Internacional S.A.
  • GlaxoSmithKline plc
  • Grünenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Ipsen S.A.
  • Johnson & Johnson
  • Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.98 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.01 Billion
Compound Annual Growth Rate8.9%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Migraine Drugs Market Size, Share, Trends and Forecast by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region, 2026-2034 - Product Image

Migraine Drugs Market Size, Share, Trends and Forecast by Treatment Type, Drug Type, Route of Administration, Distribution Channel, and Region, 2026-2034

  • Report
  • 139 Pages
  • Global
From
Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Migraine Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 185 Pages
  • Global
From
Acute Migraine Drug Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Acute Migraine Drug Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Migraine Drugs - Global Strategic Business Report - Product Image

Migraine Drugs - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From

About the Migraine Drug Market

The Migraine Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Migraine drugs are used to treat the symptoms of migraine headaches, such as nausea, vomiting, and sensitivity to light and sound. These drugs can be divided into two categories: abortive and preventive. Abortive drugs are taken at the onset of a migraine attack to reduce the severity of symptoms, while preventive drugs are taken on a regular basis to reduce the frequency of migraine attacks. Common abortive drugs include triptans, ergot alkaloids, and non-steroidal anti-inflammatory drugs (NSAIDs). Common preventive drugs include beta-blockers, anticonvulsants, and serotonin receptor agonists. Some companies in the Migraine Drug market include GlaxoSmithKline, Pfizer, Novartis, Merck, and Allergan. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.